Cardiol Therapeutics Inc.
CRDL.TO
TSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 28.49% | -19.81% | -4.56% | 1.16% | 37.40% |
| Total Depreciation and Amortization | 0.00% | 1.09% | 5.75% | -49.71% | -76.53% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -29.57% | 17.55% | 155.65% | -20.47% | -79.73% |
| Change in Net Operating Assets | -0.15% | -193.10% | 558.60% | -114.95% | 136.10% |
| Cash from Operations | 25.45% | -52.87% | 34.02% | -24.75% | 29.85% |
| Capital Expenditure | 0.00% | 53.19% | 43.37% | -88.64% | 24.14% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 0.00% | 53.19% | 43.37% | -88.64% | 24.14% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.00% | 0.00% | 0.00% | 0.00% | -200.00% |
| Issuance of Common Stock | -- | -100.00% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 110,515.84% | -168.24% | 254.17% | -100.07% | 392,805.88% |
| Foreign Exchange rate Adjustments | -240.32% | 166.12% | -439.95% | -106.55% | 540.69% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 247.22% | -29.52% | 27.44% | -148.37% | 275.98% |